Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly Net Income towards Common Stockholders of $5.6 million for Q1 2026, down 63.46% year-on-year from $15.3 million in Q1 2025, and down 52.34% on a QoQ basis from $11.7 million in Q4 2025.
Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Net Income towards Common Stockholders for 10 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 63.46% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $802.1 million (down 35.01% YoY) and the FY2026 annual result came in at -$42.4 million, down 110.4% from the prior year.
- Net Income towards Common Stockholders declined to $5.6 million in Q1 2026 per ACB's latest filing, from $11.7 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ACB reached as high as $860.2 million in Q1 2022 and fell as low as -$545.4 million in Q4 2022.
- A 5-year average of $165.5 million and a median of $359.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 4195.43% — and 2025, when it soared 1023.24%.
- Year by year, Net Income towards Common Stockholders stood at -$545.4 million in 2022, then soared by 169.56% to $379.4 million in 2023, then climbed by 8.11% to $410.1 million in 2024, then tumbled by 97.14% to $11.7 million in 2025, then tumbled by 52.34% to $5.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $5.6 million, $11.7 million, and $386.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Aurora Cannabis | 153.98 Mn | 68.73 Mn | 21.72 Mn | 5.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.58 Mn |
| Dec 31, 2025 | 11.71 Mn |
| Sep 30, 2025 | 386.51 Mn |
| Jun 30, 2025 | 398.33 Mn |
| Mar 31, 2025 | 15.27 Mn |
| Dec 31, 2024 | 410.12 Mn |
| Sep 30, 2024 | 398.17 Mn |
| Jun 30, 2024 | 410.62 Mn |
| Mar 31, 2024 | -1.65 Mn |
| Dec 31, 2023 | 379.35 Mn |
| Sep 30, 2023 | 375.79 Mn |
| Jun 30, 2023 | 354.16 Mn |
| Mar 31, 2023 | 359.55 Mn |
| Dec 31, 2022 | -545.38 Mn |
| Sep 30, 2022 | -515.60 Mn |
| Jun 30, 2022 | -488.98 Mn |
| Mar 31, 2022 | 860.20 Mn |
| Dec 31, 2021 | 1.55 Bn |
| Sep 30, 2021 | -12.00 Mn |
| Jun 30, 2021 | -87.26 Mn |